Antihemophilic factor (recombinant), PEGylated

Identification

Brand Names
Adynovate
Generic Name
Antihemophilic factor (recombinant), PEGylated
DrugBank Accession Number
DB09329
Background

Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product Adynovate Label.

Antihemophilic Factor (Recombinant), PEGylated, is a recombinant full-length human coagulation factor VIII (2,332 amino acids with a molecular weight (MW) of approximately 280 kDa) covalently conjugated with at least one molecule of polyethylene glycol (MW 20 kDa) Label. It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events 2, 3, Label.

PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma 7.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Protein Chemical Formula
Not Available
Protein Average Weight
284.0 Da
Sequences
Not Available
Synonyms
  • Antihemophilic Factor (Recombinant), PEGylated
  • antihemophilic factor (recombinant), PEGylated-aucl
External IDs
  • BAY 94-9027

Pharmacology

Indication

For the management of hemophilia A (congenital factor VIII deficiency) Label, 1. This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease Label.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

This drug temporarily replaces the missing coagulation factor VIII, required for effective hemostasis in patients with congenital hemophilia A Label.

Hemophilia A patients have a deficiency of factor VIII, resulting in a prolonged, patient plasma clotting time as demonstrated by the activated partial thromboplastin time (aPTT). Treatment with recombinant factor VIII normalizes the aPTT. Hemophilia A is a sex-linked hereditary disorder of blood coagulation caused by decreased levels of Factor VIII activity, resulting in severe bleeding into the joints, muscles or internal organs, spontaneously/as a result of trauma 18, 6.

Mechanism of action

PEG with Factor VIII effectively increases the molecular weight and size of the protein by creating a hydrophilic cloud around the molecule. This molecular change may reduce the susceptibility of this molecule to proteolytic degradation. It is also believed that PEGylation alters the surface charge of the protein that inhibits receptor-mediated clearance 4. This drug reduces binding to the LRP1 receptor, which normally clears factor VIII from the circulation 5, Label.

The plasma levels of Factor VIII are increased with replacement therapy, which allows for a temporary correction of the factor deficiency, thus a correction of the bleeding tendency 18.

TargetActionsOrganism
Avon Willebrand factor
binder
Humans
Absorption

AUC0-Inf [IU·h/dL]:

1642 ± 752 in children aged 12 to <18 years Label 2264 ± 729 in adults ≥18 years Label

Volume of distribution

At steady state: 0.56 ± 0.18 dL/Kg in children aged 12 to <18 years Label 0.43 ± 0.11 dL/kg in adults aged ≥18 years Label

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

14.69 ± 3.79h for adults aged ≥18 years Label

13.43 ± 4.05 for children 12 to <18 years Label

Clearance

2.27 ± 0.84 for adults ≥18 years Label

3.87 ± 3.31 for children 12 to <18 years Label

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Common adverse reactions reported in ≥1% of subjects in the clinical studies were headache and nausea Label,Label.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Abciximab.
AceclofenacAceclofenac may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AcenocoumarolThe therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Acenocoumarol.
AcetaminophenAcetaminophen may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
AcrivastineAntihemophilic factor (recombinant), PEGylated may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AdynovateKit; Powder, for solution1500 unit / vialIntravenousTakedaNot applicableNot applicableCanada flag
AdynovateKit; Powder, for solution2000 unit / vialIntravenousTakeda2018-03-06Not applicableCanada flag
AdynovateKit; Powder, for solution500 unit / vialIntravenousTakeda2021-08-13Not applicableCanada flag
AdynovateKit; Powder, for solution3000 unit / vialIntravenousTakeda2020-09-15Not applicableCanada flag
AdynovateKit; Powder, for solution250 unit / vialIntravenousTakeda2018-03-06Not applicableCanada flag
AdynovateKit; Powder, for solution750 unit / vialIntravenousTakedaNot applicableNot applicableCanada flag
AdynovateKit; Powder, for solution1000 unit / vialIntravenousTakeda2021-08-13Not applicableCanada flag
AdynovateKit; Powder, for solution1000 unit / vialIntravenousTakeda2018-03-06Not applicableCanada flag
AdynovateKit; Powder, for solution250 unit / vialIntravenousTakeda2021-07-16Not applicableCanada flag
AdynovateKit; Powder, for solution1500 unit / vialIntravenousTakedaNot applicableNot applicableCanada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Not Available
CAS number
1628187-15-4

References

General References
  1. Dunn AL, Ahuja SP, Mullins ES: Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A. Haemophilia. 2018 Jan 23. doi: 10.1111/hae.13403. [Article]
  2. Wynn TT, Gumuscu B: Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. 2016 Jun 20;7:121-8. doi: 10.2147/JBM.S82457. eCollection 2016. [Article]
  3. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D: Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8. doi: 10.1111/jth.12161. [Article]
  4. Chavin SI: Factor VIII: structure and function in blood clotting. Am J Hematol. 1984 Apr;16(3):297-306. [Article]
  5. Bovenschen N, van Dijk KW, Havekes LM, Mertens K, van Vlijmen BJ: Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice. Br J Haematol. 2004 Sep;126(5):722-5. doi: 10.1111/j.1365-2141.2004.05093.x. [Article]
  6. Coppola A, Di Capua M, Di Minno MN, Di Palo M, Marrone E, Ierano P, Arturo C, Tufano A, Cerbone AM: Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med. 2010;1:183-95. doi: 10.2147/JBM.S6885. Epub 2010 Aug 30. [Article]
  7. Adynovate Pro [Link]
  8. Adynovate assessment report EMA [Link]
  9. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients [Link]
  10. Potential role of a new PEGylated recombinant factor VIII for hemophilia A [Link]
  11. Potential role of a new PEGylated recombinant factor VIII for hemophilia A [Link]
  12. PEGylation of a Factor VIII–Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice [Link]
  13. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A [Link]
  14. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII [Link]
  15. Antihemophilic Factor (Recombinant [Pegylated]) [Link]
  16. EMA label Adate [Link]
  17. F8 gene coagulation factor VIII [Link]
  18. Advate Product Monograph [Link]
PubChem Substance
347910440
RxNav
1741397
FDA label
Download (474 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHemophilia As1
4Not Yet RecruitingTreatmentHemophilia As / Prophylaxis of Bleeding1
3CompletedTreatmentHemophilia As1
2, 3CompletedTreatmentHemophilia As1
1CompletedBasic ScienceHemophilia As2
1CompletedTreatmentHemophilia As1
Not AvailableCompletedNot AvailableHemophilia As1
Not AvailableRecruitingNot AvailableHemophilia As3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Kit; powder, for solutionIntravenous1000 unit / vial
Kit; powder, for solutionIntravenous1500 unit / vial
Kit; powder, for solutionIntravenous2000 unit / vial
Kit; powder, for solutionIntravenous250 unit / vial
Kit; powder, for solutionIntravenous3000 unit / vial
Kit; powder, for solutionIntravenous500 unit / vial
Kit; powder, for solutionIntravenous750 unit / vial
Injection, powder, lyophilized, for solutionIntravenous1000 IU
Injection, powder, lyophilized, for solutionIntravenous1500 IU
Injection, powder, lyophilized, for solutionIntravenous2000 IU
Injection, powder, lyophilized, for solutionIntravenous250 IU
Injection, powder, lyophilized, for solutionIntravenous3000 IU
Injection, powder, lyophilized, for solutionIntravenous500 IU
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
General Function
Protein n-terminus binding
Specific Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
Gene Name
VWF
Uniprot ID
P04275
Uniprot Name
von Willebrand factor
Molecular Weight
309261.83 Da
References
  1. Chavin SI: Factor VIII: structure and function in blood clotting. Am J Hematol. 1984 Apr;16(3):297-306. [Article]
  2. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D: Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8. doi: 10.1111/jth.12161. [Article]
  3. F8 gene coagulation factor VIII [Link]
  4. Adynovate FDA label [File]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein n-terminus binding
Specific Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
Gene Name
VWF
Uniprot ID
P04275
Uniprot Name
von Willebrand factor
Molecular Weight
309261.83 Da
References
  1. Chavin SI: Factor VIII: structure and function in blood clotting. Am J Hematol. 1984 Apr;16(3):297-306. [Article]
  2. Wynn TT, Gumuscu B: Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. 2016 Jun 20;7:121-8. doi: 10.2147/JBM.S82457. eCollection 2016. [Article]
  3. Adynovate FDA label [File]

Drug created on November 18, 2015 16:20 / Updated on October 22, 2021 23:18